Healthcare Services

CCR5 market developments shaping growth

April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The CC Chemokine Receptor Type 5 Market Compare Between 2026 And 2030?

The cc chemokine receptor type 5 market size has witnessed substantial growth in recent years. It is forecast to increase from $1.54 billion in 2025 to $1.7 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.1%. This expansion in the past can be attributed to the identification of CCR5’s involvement in HIV infection, the early development of CCR5 inhibitors, the enlargement of immunology research initiatives, clinical investigations into inflammatory conditions, and the proliferation of targeted receptor-based treatments.

The cc chemokine receptor type 5 market size is anticipated to undergo significant expansion over the next few years. It is projected to reach $2.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.9%. This expansion throughout the forecast period is driven by factors such as the broadening of personalized immunotherapies, increasing innovation in HIV treatment, growing oncology drug development pipelines, rising investment in immune modulation research, and advancements in targeted receptor drug design. Significant trends expected in this period include the escalating development of CCR5 antagonist therapies, an increased focus on HIV and immunology research, the widening of CCR5 applications in oncology, the growing adoption of targeted immune modulation strategies, and an intensified emphasis on precision drug development.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report

Which Strong Drivers Are Impacting The CC Chemokine Receptor Type 5 Market Growth?

The growing incidence of chronic diseases is projected to drive the CC chemokine receptor type 5 market forward. Chronic diseases are defined as long-term health conditions, such as heart disease, diabetes, and arthritis, which progress slowly and often require continuous management. The rise in chronic disease prevalence is attributed to an aging global population and increasing rates of lifestyle-related risk factors including poor diet, physical inactivity, and obesity. CC Chemokine Receptor Type 5 (CCR5) plays a vital role in chronic diseases like human immunodeficiency virus (HIV), functioning as a coreceptor that enables the virus to enter and infect immune cells, thereby significantly contributing to disease progression. For example, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, approximately 194 million U.S. adults, or 76.4%, reported experiencing at least one chronic condition in 2023. The prevalence was recorded at 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the increasing prevalence of chronic diseases is boosting the growth of the CC chemokine receptor type 5 market.

Which Segments Define The CC Chemokine Receptor Type 5 Market Segment Structure?

The cc chemokine receptor type 5 market covered in this report is segmented –

1) By Type: BMS-813160, AG-1105, DS-001, Other Types

2) By Distribution Channel: Hospitals, Clinics

3) By Application: Infectious Disease, Immunology, Oncology, Other Applications

4) By End User: Research Institutes, Pharmaceutical Companies, Healthcare Facilities

Subsegments:

1) By BMS-813160: CCR5 Antagonist For HIV Treatment, CCR5 Antagonist For Inflammatory Diseases

2) By AG-1105: CCR5 Antagonist For Autoimmune Disorders, CCR5 Antagonist For Cancer Therapy

3) By DS-001: CCR5 Inhibitor For Cancer Treatment, DS-001 For Inflammatory Disease Management

4) By Other Types: Novel CCR5 Antagonists, Dual-Target CCR5 Antagonists

Which Trends Are Contributing To Changes In The CC Chemokine Receptor Type 5 Market?

Companies operating in the CC chemokine receptor type 5 market are primarily focused on developing novel drugs, such as a CCR5 antagonist, to gain a competitive edge. A CCR5 antagonist functions as a medication that blocks the CC chemokine receptor type 5 (CCR5) receptor on immune cells, thereby preventing specific pathogens like HIV from binding and entering these cells, which inhibits infection and modulates immune responses. For instance, in February 2024, CytoDyn Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on leronlimab. This enables the company to proceed with its planned HIV clinical trial, which will investigate leronlimab’s effects on chronic inflammation. Leronlimab, a CCR5 antagonist also known as PRO 140, holds significant promise for various therapeutic uses, given its ability to target multiple health conditions, and is currently being studied for different indications, including HIV and cancer.

Who Are The Established Players Within The CC Chemokine Receptor Type 5 Market?

Major companies operating in the cc chemokine receptor type 5 market are Cytodyn Inc., Gilead Sciences Inc., ViiV Healthcare Limited, Pfizer Inc., Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, AbbVie Inc., AstraZeneca plc, Novartis AG, Sanofi SA, Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Ono Pharmaceutical Co Ltd, Avexa Limited, Incyte Corporation, Humanigen Inc., Biogen Inc.

Get The Full CC Chemokine Receptor Type 5 Market Report:

https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report

Which Region Holds The Highest Market Share In The CC Chemokine Receptor Type 5 Market?

North America was the largest region in the CC chemokine receptor type 5 market in 2025. The regions covered in the cc chemokine receptor type 5 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized CC Chemokine Receptor Type 5 Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report

Browse Through More Reports Similar to the Global CC Chemokine Receptor Type 5 Market 2026, By The Business Research Company

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

C X C Chemokine Receptor 4 Cxcr4 Antagonists Market Report 2026

https://www.thebusinessresearchcompany.com/report/c-x-c-chemokine-receptor-4-cxcr4-antagonists-global-market-report

Chemoinformatics Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemoinformatics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795